Positions

Overview

  • I am a pediatric oncologist with a clinical focus on solid tumors and research focus on disparities in end-of-life care. I am originally from Iowa, went to Carleton College in Minnesota for undergraduate before heading to Stanford for my medical training (medical school, residency, and fellowship). I joined the UAB faculty July 2018.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 Financial hardships and psychosocial outcomes among parents of children who die of cancer.  Pediatric Blood and Cancer.  70. 2023
    2022 Development of Primary Palliative Care End-of-Life Quality Measures: A Modified Delphi Process.  Pediatrics.  150. 2022
    2022 Charting a path to high-quality end-of-life care for children with cancer.  Cancer.  128:3586-3592. 2022
    2022 Survey of Pediatric Palliative Care Quality Improvement Training, Activities, and Barriers.  Journal of Pain and Symptom Management.  64:e123-e131. 2022
    2022 Location of death and hospice use in children with cancer varies by type of health insurance.  Pediatric Blood and Cancer.  69. 2022
    2022 SARS-CoV-2 vaccine acceptability among caregivers of childhood cancer survivors.  Pediatric Blood and Cancer.  69. 2022
    2022 A “Good Death” for Children with Cardiac Disease.  Pediatric Cardiology.  43:744-755. 2022
    2022 Caregiver Reported Quality of End-of-Life Care of Adolescent and Young Adult Decedents With Cancer.  Journal of Palliative Care.  37:87-92. 2022
    2022 COVID-19 in Children with Cancer.  Current Oncology Reports.  24:295-302. 2022
    2022 Pediatric Palliative Care Parents’ Distress, Financial Difficulty, and Child Symptoms.  Journal of Pain and Symptom Management.  63:271-282. 2022
    2022 Early palliative care is associated with less intense care in children dying with cancer in Alabama: A retrospective, single-site study.  Cancer.  128:391-400. 2022
    2021 SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities.  Journal of Clinical Oncology.  39:3778-3788. 2021
    2021 Polysymptomatology in Pediatric Patients Receiving Palliative Care Based on Parent-Reported Data.  JAMA Network Open.  4. 2021
    2021 Quality measures for end-of-life care for children with cancer: A modified Delphi approach.  Cancer.  127:2571-2578. 2021
    2021 Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma—A population-based study.  Pediatric Blood and Cancer.  68. 2021
    2021 Risk, Racial Disparity, and Outcomes among Patients with Cancer and COVID-19 Infection.  JAMA Oncology.  7:1064-1065. 2021
    2021 Impacts of COVID-19 on caregivers of childhood cancer survivors.  Pediatric Blood and Cancer.  68. 2021
    2021 To Disclose or Not to Disclose: A Case Highlighting the Challenge of Conflicts in Pediatric Disclosure.  Journal of Pain and Symptom Management.  61:211-215. 2021
    2020 Palliative Care Knowledge and Characteristics in Caregivers of Chronically Ill Children.  Journal of Hospice and Palliative Nursing.  22:456-464. 2020
    2020 Riverview Terrace Team: A Novel Special Operations Forces Medic Role Emerges at the Forefront of the Fight Against COVID-19.  Journal of special operations medicine : a peer reviewed journal for SOF medical professionals.  20:136-138. 2020
    2020 Bereaved parents' views on end-of-life care for children with cancer: Quality marker implications.  Cancer.  126:3352-3359. 2020
    2020 Hospital or Home? Where Should Children Die and How Do We Make That a Reality?.  Journal of Pain and Symptom Management.  60:106-115. 2020
    2020 Better Understanding the Importance of Palliative Care for Pediatric Patients.  JAMA Oncology.  6:817-818. 2020
    2020 Acute Care Utilization at End of Life in Sickle Cell Disease: Highlighting the Need for a Palliative Approach.  Journal of Palliative Medicine.  23:24-32. 2020
    2019 Supporting Family Caregivers of Adult and Pediatric Persons with Leukemia.  Seminars in Oncology Nursing.  35. 2019
    2019 Disparities in inpatient intensity of end-of-life care for complex chronic conditions.  Pediatrics.  143. 2019
    2018 End-of-life care intensity in patients undergoing allogeneic hematopoietic cell transplantation: A population-level analysis.  Journal of Clinical Oncology.  36:3023-3030. 2018
    2018 Inpatient utilization and disparities: The last year of life of adolescent and young adult oncology patients in California.  Cancer.  124:1819-1827. 2018
    2018 The Patient Protection and Affordable Care Act dependent coverage expansion: Disparities in impact among young adult oncology patients.  Cancer.  124:110-117. 2018
    2017 Disparities in location of death of adolescents and young adults with cancer: A longitudinal, population study in California.  Cancer.  123:4178-4184. 2017
    2017 Disparities in the intensity of end-of-life care for children with cancer.  Pediatrics.  140. 2017
    2017 Pediatric-specific end-of-life care quality measures: an unmet need of a vulnerable population.  Jco Oncology Practice.  13:e874-e880. 2017
    2017 End-of-life intensity for adolescents and young adults with cancer: A californian population-based study that shows disparities.  Jco Oncology Practice.  13:e770-e781. 2017
    2017 Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers.  Cancer.  123:2516-2523. 2017
    2016 In Their Own Voices: The Reproductive Health Care Experiences of Detained Adolescent Girls.  Women's Health Issues.  26:48-54. 2016
    2015 Subcutaneous panniculitis-like T-cell lymphoma: Pediatric case series demonstrating heterogeneous presentation and option for watchful waiting.  Pediatric Blood and Cancer.  62:2025-2028. 2015
    2010 Long-term outcome following pediatric liver transplantation for metabolic disorders.  Pediatric Transplantation.  14:268-275. 2010

    Research Overview

  • My long-term goal is to establish EOL quality measures for children with cancer and leverage the measures to reduce disparities in EOL care. Cancer is the leading cause of disease-related death in children in the US, making it critical to optimize the quality of end of life (EOL) care received by children with cancer. However, there are no EOL quality measures for children with cancer. In contrast, there are National Quality Forum (NQF)-endorsed EOL quality measures for adults with cancer. These measures were essential in identifying disparities in EOL care in adults with cancer; underrepresented minorities and publicly insured are less likely to receive quality EOL care, informing pivotal intervention research to mitigate disparities. Lack of EOL quality measures for children dying with cancer prevents us from examining disparities in EOL care.

    • Principal Investigator On

  • Developing Quality Measures for End-of-Life Care for Children with Advanced Heart Disease  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • End-of-Life Care of AL Children with Cancer: Disparities and Parent Priorities  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • End-of-Life Care of Children with Cancer: Variation and Stakeholder Priorities  awarded by Alex's Lemonade Stand
  • Exploring the Feasibility, Validity, and Reliability of the Collection of End-of-Life Quality Measure Data in Children with Serious Illness  awarded by SEATTLE CHILDREN'S HOSPITAL
  • Financial Toxicity at End-of-Life and Beyond  awarded by Alex's Lemonade Stand
  • Hospice Use at End-of-Life in Children with Cancer  awarded by St. Baldrick's Foundation
  • Hospice Use at the End-of-Life in Children with Cancer  awarded by Conquer Cancer Foundation of ASCO
  • Intensity of End-of-Life Care of Children, Adolescents, and Young Adults with Hematologic Malignancies: Rates, Disparities, and Appropriateness  awarded by Leukemia and Lymphoma Society
  • Pediatric Palliative Care Research Network SHARE Study  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Promoting Resilience in Stress Management (PRISM)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Quality of End-of-Life Care for Children with Cancer: Can We Measure It Across Diverse Populations  awarded by American Cancer Society, Inc.
  • Quality of End-of-Life Care for Children with Cancer: Can We Measure It?  awarded by St. Baldrick's Foundation
  • Research Collaboration Agreement with Duke University  awarded by Duke University
  • Research Collaboration Agreement with Duke University  awarded by Duke University
  • Research Services Agreement with Boston Children's Hospital  awarded by BOSTON CHILDREN'S HOSPITAL

    • Investigator On

  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ANBL1531-JDI- A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL),”  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • APEC1621I -NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • APEC1621SC - PEDIATRIC MATCH PCR - COG FOUNDATION  awarded by CHILDREN'S ONCOLOGY GROUP
  • ARST1921, A Safety, Pharmacokinetic and Efficacy Study of a ?-Secretase Inhibitor, Nirogacestat(PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors -AR10441  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • ARST1921, A Safety, Pharmacokinetic and Efficacy Study of y-Secretase Inhibitor, Nirogacestat (PF03084014:IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Continuation of Tyrosine Kinase Inhibitors after Chemotherapy in Pediatric Ph+ ALL: A Multi-site Retrospective Study  awarded by Stanford University
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • End-of-Life Care of Children with Cancer: Variation and Stakeholder Priorities  awarded by Alex's Lemonade Stand
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intensity of End-of-Life Care of Children, Adolescents, and Young Adults with Hematologic Malignancies: Rates, Disparities, and Appropriateness  awarded by Leukemia and Lymphoma Society
  • Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • MCC 18613 Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 18613, Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 19487 A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with 5-Azacytidine in Patients with Recurrent, Resectable Osteosarcoma  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 20339 Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • PEPN2112- A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Pediatric Oncology COVID Cancer Case Report - A National Registry of Children with Cancer (POCC)  awarded by Concern Foundation
  • Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Private Grant  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Private Grant  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Private Grant  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Private Grant  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Workload Intensity NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)

    • Education And Training

  • Master of Science in Health Policy Analysis, Stanford University 2018
  • Doctor of Medicine, Stanford University 2010

    • Full Name

  • Emily Johnston